Thetis is a biopharmaceutical company developing potential first-in-class therapies for autoimmune and inflammatory diseases.
Thetis is a biopharmaceutical company with platform technology developing first-in-class therapies for treatment of inflammatory diseases. Thetis’ drug candidates are based on a novel class of pro-resolving mediators (“Resolvins”) discovered by biomedical scientists at Harvard Medical School. Their pioneering research has shown that Resolvins are potent agonists of inflammation resolution and tissue repair that can be delivered therapeutically to counteract an overactive inflammatory response without compromising immune function.
Thetis’ HEALER™ technology platform enables the development of Resolvins and other bioactive lipids as new molecular entities with enhanced stability and bioavailability, overcoming key hurdles that have historically limited their development as pharmaceutical drugs. Thetis is leveraging this technology to develop a pipeline of drug candidates for treatment of autoimmune and inflammatory diseases.
Our lead candidate is a novel Resolvin E1 small molecule therapy (TP-317) being developed for inflammatory bowel disease (IBD) and acute respiratory distress syndrome (ARDS). TP-317 offers a differentiated therapeutic strategy for treatment of both diseases that harnesses natural resolution mechanisms without suppressing the immune system.